Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetra DIIIC
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intraperitoneal
01
Overview
Tetra DIIIC is a tetravalent recombinant protein vaccine candidate developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, for the prevention of dengue fever. The vaccine utilizes a unique platform of chimeric proteins that fuse domain III of the envelope protein with the capsid protein from all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). This design is intended to induce both neutralizing antibodies and a robust cellular immune response against all four serotypes simultaneously, aiming to reduce viral load and prevent severe disease. As of 2023, the candidate is in the evaluation phase, with its technological platform validated as safe.
- Other names
- CIGB dengue vaccinetetravalent recombinant dengue vaccine
02
Targets
C protein (Dengue virus capsid protein)DENV (Flavivirus antigens and proteins)TLR9 (Toll-like receptor 9)MHC I (MHC class I})
Beyond the preview
Go deeper on Tetra DIIIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetra DIIIC.